SEQLL INC DL-,00001 Aktie Logo
US81734C1062

SEQLL INC DL-,00001 Aktie

Ins Portfolio

Kurse werden geladen...

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

  • Foto von SeqLL Defers Proposed Cash and Stock Distributions to Stockholders in Connection With Proposed Acquisition

    SeqLL Defers Proposed Cash and Stock Distributions to Stockholders in Connection With Proposed Acquisition

    BILLERICA, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), today announced the decision of its Board of Directors to cancel the special cash dividend and stock dividend that it intended to make to its common stockholders in connection with, and subject to, the consummation of its planned acquisition of Lyneer Investments LLC (“Lyneer”) and the disposition of its current business operations.» Mehr auf globenewswire.com

  • Foto von SeqLL Announces Cash and Stock Dividend Record Date

    SeqLL Announces Cash and Stock Dividend Record Date

    BILLERICA, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), announced today that its board of directors has set September 26, 2023 as the record date for its special stock dividend and cash dividend to be made to the holders of its common stock pursuant to the terms of the Agreement and Plan of Reorganization dated as of May 29, 2023, as amended (the “Merger Agreement”), by and among the Company, SeqLL Merger LLC, Atlantic Acquisition Corp., Atlantic Merger LLC, Lyneer Investments, LLC, IDC Technologies, Inc. and Lyneer Management Holdings LLC. The dividend distribution of shares of common stock of the Company and the cash dividend will be made to all SeqLL common stockholders of record as of the close of business on September 26, 2023 (the "Record Date"). The cash and stock dividends, which are contingent upon, and subject to, the consummation of the transactions contemplated by the Merger Agreement, are expected to be completed on or about October 2, 2023 (the "distribution date"), subject to certain conditions.» Mehr auf globenewswire.com

  • Foto von SeqLL to Conduct 1-for-40 Reverse Stock Split

    SeqLL to Conduct 1-for-40 Reverse Stock Split

    BILLERICA, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), a technology company providing life sciences instrumentation and research services, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-40. The reverse stock split will become effective at 11:59 p.m. Eastern Time, on August 30, 2023. The Company's common stock will begin trading on a post-split basis at the market open on August 31, 2023, under the Company's existing trading symbol "SQL". The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Jahr hatte SEQLL INC DL-,00001 Aktie einen Umsatz von +1,10k und ein Nettoeinkommen von 3,91 Mio
(EUR)2022
YOY
Umsatz+1,10k97,40%
Bruttoeinkommen+454,01105,34%
Nettoeinkommen3,91 Mio13,78%
EBITDA3,64 Mio67,92%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+2,29 Mio
Anzahl Aktien
380,65k
52 Wochen-Hoch/Tief
+6,17 - +6,17
DividendenNein
Beta
1,29
KGV (PE Ratio)
0,47
KGWV (PEG Ratio)
0,05
KBV (PB Ratio)
+0,45
KUV (PS Ratio)
+2.134,18

Unternehmensprofil

SeqLL Inc. ist ein weltweit tätiges Unternehmen für Life-Science-Instrumente und Forschungsdienstleistungen. Das Unternehmen entwirft, entwickelt und fertigt Technologien für die Genanalyse. Es bietet eine Plattform für echte Einzelmolekülsequenzierung (tSMS), die eine Einzelmoleküllösung für die DNA- und RNA-Sequenzierung bietet. Das Unternehmen hat ein Kooperationsabkommen mit Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc. und Tetracore, Inc. Das Unternehmen beliefert akademische und staatliche Einrichtungen, Krankenhäuser und medizinische Zentren, Pharma- und Biotechnologieunternehmen sowie gemeinnützige Forschungsorganisationen. Das Unternehmen wurde im Jahr 2013 gegründet und hat seinen Sitz in Billerica, Massachusetts.

Name
SEQLL INC DL-,00001 Aktie
CEO
Daniel Robert Jones
SitzBillerica, ma
USA
Website
Industrie
Gesundheitswesen: Ausstattung und Produkte
Börsengang
Mitarbeiter7

Ticker Symbole

BörseSymbol
NASDAQ
SQL
🍪

Parqet nutzt Cookies.Erfahre Mehr